From the advances made in immunology in some tumors in the past two years, it can be predicted that tumor patients may actually achieve tumor-bearing survival in the next 20 years. The progress of immunotherapy includes anti-CTLA-4 monoclonal antibody, anti-PD-1 monoclonal antibody and anti-PD-L1 monoclonal antibody in the treatment of malignant melanoma, renal cancer and some solid tumors, such as lung cancer, etc. The clinical application of these drugs is that the survival of some patients has been significantly prolonged, and a considerable number of patients (20%) can obtain long-term survival. The most important thing is that the treatment will not bring the patients pain like chemotherapy, radiotherapy and surgery. However, these drugs have not yet entered China, and the effect in solid tumors such as lung cancer, intestinal cancer, stomach cancer, etc. has to be further prolonged. It is also hoped that these drugs are not too expensive, so that most of the people can afford them; or it is hoped that China’s health insurance can be reimbursed (unlikely); In addition, some individualized secondary immune cell therapy has made progress in some epithelial tumors, which has shown a ray of light in the dark sky of late-stage tumor treatment. However, these individualized immune cell therapies are different from the CIK cell and DC cell tumor seedling cell therapies (which are basically ineffective) that are now practiced in major hospitals.